Market Research Report
Global Ovarian Cancer Drugs Market 2019-2025
|Published by||Orion Market Research Pvt Ltd||Product code||505712|
Delivery time: 2-3 business days
|Global Ovarian Cancer Drugs Market 2019-2025|
|Published: January 3, 2020||Content info:||
Global Ovarian Cancer Drugs
Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, and PD-L1 Inhibitors) and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) and Forecast 2019-2025.
The global ovarian cancer drugs market is expected to grow at a CAGR of 13.8% during the forecast period. Ovarian cancer is one of the riskiest cancers among all cancers in females. This cancer grows inside an ovary, resulting in abnormal growth of cells that have the tendency to attack or affect the functioning of other parts of the body, such as liver, lymph nodes, abdomen layers, the lining of the bowel and bladder. The ovarian cancer is rare; however, the risk in such kind of cancer is relatively high. According to the World Health Organization (WHO), around 10% of ovarian cancer cases are related to inherited genetic risk. The market is boosted by the increasing incidence of ovarian cancer, which is rising the need for more effective treatment. The high cost of ovarian cancer drugs and inaccurate diagnostic of ovarian cancer acts as a barrier for the growth of the market.
Geographically, the global ovarian cancer drugs market is classified into North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to have a significant share in the global market. The factors that are contributing to the market growth include the increasing prevalence of ovarian cancer, well-established healthcare infrastructure coupled with the presence of major market players in the region. Moreover, Asia-Pacific is estimated to exhibit considerable market growth in the global market during the forecast period. The rising awareness towards the ovarian cancer treatment in emerging economies, such as China and India, along with increasing healthcare expenditure and government initiatives are propelling the market growth in the region.
The global ovarian cancer drugs market is influenced by product development and advancements conducted by the market players. The key players operating in the global ovarian cancer drugs market include AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Eli Lilly and Co., Bristol-Myers Squibb Co., and ImmunoGen Inc. These players are playing a significant role in the growth of the ovarian cancer drugs market by providing various products and adopting several strategies such as a merger and acquisition, partnerships and collaboration, technological development, and others. For instance, in December 2018, AstraZeneca PLC and Merck & Co., Inc. has received an FDA approval for olaparib (LYNPARZA) for the treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, who are under the complete or some response to first-line platinum-based chemotherapy.
The market study of the global ovarian cancer drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
The report is intended for a healthcare service provider, pharmaceutical companies, investing companies, government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.